

Electronic Supporting Information (ESI)

Visible light promoted tandem dehydrogenation-deaminative cyclocondensation under aerobic condition for the synthesis of 2-aryl benzimidazoles/quinoxalines from *ortho*-phenylenediamines and arylmethyl/ethyl amines

Firdoos Ahmad Sofi,^a Rohit Sharma,^{a,b} Ravi Rawat,^a Asit K. Chakraborti^{a,c,*} and Prasad V. Bharatam^{a,*}

^aDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, Punjab-160062, India

^bPresent address: Department of Forest Product, College of Forestry, Dr. Y.S. Parmar University of Horticulture and Forestry, Nauni, Solan, India

^cPresent address: Department of Chemistry, Indian Institute of Technology-Ropar, Rupnagar, Punjab- 140001, India

*Corresponding authors' e mails: pvbharatam@niper.ac.in (P V Bharatam); akchakraborti@niper.ac.in, chakrabortiak@iitrpr.ac.in (A K Chakraborti).

TABLE OF CONTENTS

Section	Contents
1.	Experimental procedures and spectral data
2.	Scanned ¹ H, ¹³ C NMR and HRMS spectra
3.	References associated with ESI

SECTION 1. EXPERIMENTAL PROCEDURES AND SPECTRAL DATA

Experimental Procedures:

S1.1. General. The chemicals required for the study were obtained from Sigma-Aldrich Company and were used as such without further purification unless otherwise mentioned. Thin Layer Chromatography (TLC) performed on silica gel aluminium plates monitored the progress of the reaction and visualization was done by UV chamber. ^1H NMR and ^{13}C NMR spectra were recorded at 400 MHz and 100 MHz instrument respectively, with TMS as an internal standard. Chemical data for protons are reported in parts per million (ppm) downfield from tetramethylsilane and are referenced to the residual proton in the NMR solvent (CDCl_3 , 7.26 ppm; CD_3OD , 3.31 ppm; $\text{DMSO}-d_6$ 2.51 ppm). Chemical data for carbons are reported in parts per million (ppm, δ scale) downfield from tetramethylsilane and are referenced to the carbon resonance of the solvent (CDCl_3 , 77.16 ppm; CD_3OD , 49.0; $\text{DMSO}-d_6$ 39.51 ppm). Coupling constants (J) were reported in hertz (Hz). The abbreviations used to characterize the signals are as follows: s = singlet, m = multiplet, d = doublet, br. s. = broad singlet, dd = doublet of doublet, t = triplet. ESI-MS spectra were recorded on Agilent 1100 LC-Q-TOF. IR spectra were recorded on Perkin-Elmer IR spectrophotometer.

Typical procedure for the synthesis of 2-phenyl-1*H*-benzo[*d*]imidazole: To the magnetically stirred mixture of the *o*-phenylenediamine **1a** (108.1 mg, 1 mmol) and benzylamine **2a** (128.5 mg, 1.2 mmol, 131.07 μL) in DMSO (4 mL) was added aq. HCl (0.864 mg, 0.24 mmol, 24 mol%: 20 μL of aq. 12 N HCl) and the mixture was irradiated with visible light (White CFL, 32 W) for 30 h. After completion of the reaction (TLC), the mixture was diluted with water (5 mL) and extracted with EtOAc (3×5 mL). The combined EtOAc extracts were dried (anh Na_2SO_4), filtered, the filtrate concentrated under rotary vacuum evaporation, and the residue was charged on to chromatography (100-200 mesh silica gel) column and eluted with 12% EtOAc-hexane to afford pure **3a** (151.4 mg, 78%). All the remaining reactions were performed on 1 mmol scale following this general procedure and. The spectral data of the synthesised compounds are provided below.

Experimental procedure for the synthesis of 2-aryl quinoxalines: To the magnetically stirred mixture of the *o*-phenylenediamine **1a** (108.1 mg, 1 mmol) and phenethylamine **4a** (145.4 mg, 150.8 μL , 1.2 mmol) in DMSO (4 mL) was added HCl (0.864 mg, 0.24 mmol, 24 mol%: 20 μL of aq. 12 N HCl) and irradiated under visible light (White CFL, 32 W) for 30 h. After completion of

the reaction (TLC), the mixture was diluted with water (5 mL) and extracted with EtOAc (3×5 mL). The combined EtOAc extracts were dried (anh Na₂SO₄), filtered, the filtrate was concentrated under rotary vacuum evaporation, the residue was charged on to chromatography (100-200 mesh silica gel) column and eluted with 10% EtOAc-hexane to afford pure **5a** (154.6 mg, 75%). All the remaining reactions were performed following this general procedure and on 1 mmol scale. The spectral data of the synthesised compounds are provided below.

Separation of the regioisomeric mixtures of **5m & **5m¹** and of **5n** & **5n¹** by column chromatography:** The separation of regioisomeric products was achieved by adsorbing the crude reaction mixture on silica gel (60-120 mesh size) and charged on the column chromatography of silica gel (230-400 mesh size) and eluting with hexane-EtOAc (98:2) to obtain the pure regioisomers. In case of separation of the regioisomeric mixture of **5m** and **5m¹**, the compound **5m** eluted first (67 mg, 30% yield) followed by the compound **5m¹** (89 mg, 40% yield). In case of separation of the regioisomeric mixture of **5n** and **5n¹**, the compound **5n** eluted first (60 mg, 25% yield) followed by the compound **5n¹** (103 mg, 43% yield).

Spectral Data:


(Note: In general, in a ¹H NMR spectrum recorded in CDCl₃, a peak at around δ 1.6 refers to moisture in the solvent/sample and a peak at δ 1.2 refers to oil/grease present in the sample. Similarly, in ¹H NMR spectrum recorded in DMSO, a peak at around δ 3.3 refers to moisture in the solvent/sample.

2-Phenyl-1*H*-benzo[*d*]imidazole (**3a**)¹




White solid; 151.4 mg, 78%, m.p 294-297 °C (295-298 °C)²; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.93 [s, 1H (NH)], 8.21 (d, *J* = 8 Hz, 2H), 7.69 (d, *J* = 8 Hz, 1H), 7.58-7.48 (m, 4H), 7.23 (t, *J* = 8 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 151.7, 144.3, 135.5, 130.6, 130.3, 129.4, 126.9, 122.9, 122.1, 119.3, 111.8; IR (CHCl₃): ν_{max} 2955.1, 2920.8, 2870.4, 1713.2, 1458.4, 1377.9, 1275, 1260.7, 1187.8, 1081.5, 1019 cm⁻¹; ESI-MS (*m/z*): 195.20 [M+H]⁺.

2-(4-Methylphenyl)-1*H*-benzo[d]imidazole (3b)²




Off white solid; 145.7 mg, 70%, m.p 266-268 °C (267-269 °C)²; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.82 [s, 1H (NH)], 8.08 (d, *J* = 8 Hz, 2H), 7.65-7.51 (m, 2H), 7.37 (d, *J* = 8 Hz, 2H), 7.22-7.17 (m, 2H), 2.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 151.8, 144.3, 140, 135.4, 129.9, 129.4, 127.9, 126.8, 122.8, 122, 119.2, 111.6, 21.4; IR (CHCl₃): ν_{max} 3405.9, 2924.7, 2255, 1657.4, 1457.1, 1378.3, 1275.6, 1260.9, 1023.5, 999.1 cm⁻¹; ESI-MS (*m/z*): 209.06 [M+H]⁺.

5,6-Dichloro-2-phenyl-1*H*-benzo[d]imidazole (3i)¹



White solid; 188.6 mg, 72%, m.p 225-227 °C (226-227 °C)⁵; ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.3 [s, 1H (NH)], 8.19 (d, *J* = 8 Hz, 2H), 7.95 (s, 1H), 7.91 (d, *J* = 8 Hz, 1H), 7.77 (s, 1H), 7.59-7.54 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 154.6, 143.8, 135.3, 131, 129.7, 128.7, 127.7, 127.1, 120.2, 113.4; IR (CHCl₃): ν_{max} 2954.9, 2922.9, 2854.2, 1711.9, 1457.5, 1378, 1275.5, 1260.8, 1189, 1081.4, 1027.9 cm⁻¹; ESI-MS (*m/z*): 340.99 [M+H]⁺.

5,6-Dimethyl-2-phenyl-1*H*-benzo[d]imidazole (3j)³




White solid; 151.0 mg, 68%, m.p 245-248 °C (246-248 °C)⁵; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.65 [s, 1H (NH)], 8.16 (d, *J* = 8 Hz, 2H), 7.55 (t, *J* = 8Hz, 2H), 7.48 (t, *J* = 8 Hz, 2H), 7.30 (s, 1H), 2.34 (s, 3H), 2.32 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 150.8, 142.9, 133.9, 131.6, 130.4, 130.8, 129.9, 129.3, 126.6, 119.4, 111.8, 20.5 IR (CHCl₃): ν_{max} 3434.9, 2251.8, 2125.6, 1770.3, 1658.4, 1451, 1376.3, 1240.2, 1031 cm⁻¹; ESI-MS (*m/z*): 223.11 [M+H]⁺.

5-Nitro-2-phenyl-1*H*-benzo[*d*]imidazole (3g)³




White solid; 181.7 mg, 76%, m.p 207-209 °C (208-209 °C)⁵; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.44 (s, 1H), 8.21 (d, *J* = 8 Hz, 2H), 8.11 (d, *J* = 8 Hz, 1H), 7.74 (d, *J* = 8 Hz, 1H), 7.59-7.57 (m, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 156.2, 144.3, 143.1, 139.5, 137.4, 131.4, 129.6, 127.4, 118.4, 116.3, 111.5; IR (CHCl₃): ν_{max} 3428.9, 2253.2, 2126.4, 1658.6, 1275.8, 1260.9, 1051.2, 1023.4, 1003.6 cm⁻¹; ESI-MS (*m/z*): 240.06 [M+H]⁺.

5-Chloro-6-nitro-2-phenyl-1*H*-benzo[*d*]imidazole (3k)




Off white low melting solid; 188.4 mg, 69%; ¹H NMR (400 MHz, DMSO-d₆) δ 8.34 (s, 1H), 8.21 (d, *J* = 8 Hz, 2H), 7.88 (s, 1H), 7.60-7.58 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 156.8, 143.1, 142.3, 138.2, 131.5, 129.6, 129.2, 127.5, 119.2, 117.1, 113.9; IR (CHCl₃): ν_{max} 3440.1, 3049.4, 2299.9, 1646.5, 1275.1, 1052.7, 1026.3, 1007.4 cm⁻¹; ESI-MS (*m/z*): 274.03 [M+H]⁺; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd for C₁₃H₉ClN₃O₂ 274.0378; Found 274.0375.

2-(3-Chlorophenyl)-1*H*-benzo[*d*]imidazole (3c)²



White solid; 175.6 mg, 77%, m.p 239-241 °C (238-240 °C)²; ¹H NMR (400 MHz, DMSO-d₆) δ 13.07 (s, 1H), 8.24 (s, 1H), 8.16 (d, *J* = 4 Hz, 1H), 7.70 (d, *J* = 4 Hz, 1H), 7.61-7.55 (m, 3H), 7.26 (t, *J* = 8 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 150, 143.9, 135.5, 134.6, 132.7, 131.4, 129.9, 126.8, 125.6, 123.4, 122.8, 119.6, 111.9; IR (CHCl₃): ν_{max} 3434.9, 2252.6, 2126.3, 1658.2, 1441.4, 1275.9, 1027.1 cm⁻¹; ESI-MS (*m/z*): 229.04 [M+H]⁺.

2-(3-Chlorophenyl)-5-nitro-1*H*-benzo[*d*]imidazole (3h)⁴




Off white solid; 218 mg, 80%; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.50 (s, 1H), 8.25 (s, 1H), 8.19-8.14 (m, 2H), 7.80 (d, *J* = 8Hz, 1H), 7.65-7.64 (m, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 154.5, 142.8, 138.2, 133.9, 131.1, 131, 126.5, 125.9; IR (CHCl₃): ν_{max} 3434.9, 2253, 2126.7, 1658.6, 1344.8, 1241.1, 1027, 1007 cm⁻¹; ESI-MS (*m/z*): 273.98 [M+H]⁺.

2-(2-Methylphenyl)-1*H*-benzo[*d*]imidazole (3d)⁵




Off white solid; 145.6 mg, 70%; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.76 (d, *J* = 4Hz, 1H), 7.63-7.61 (m, 2H), 7.43-7.35 (m, 3H), 7.24-7.20 (m, 2H), 2.62 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 152.4, 137.5, 131.7, 130.5, 129.9, 129.8, 126.4, 122.4, 21.5; IR (CHCl₃): ν_{max} 2923.4, 2853.9, 1733.9, 1457.1, 1378.2, 1260.3, 1025.2 cm⁻¹; ESI-MS (*m/z*): 208.95 [M+H]⁺.

2-(2,4-Dimethoxyphenyl)-1*H*-benzo[*d*]imidazole (3e)⁶




Off white solid; 157.5 mg, 62%; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.27 (d, *J* = 8Hz, 1H), 7.60-7.57 (m, 2H), 7.17-7.15 (m, 2H), 6.77-6.71 (m, 2H), 4.03 (s, 3H), 3.86 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 158.5, 149.6, 131.3, 121.9, 111.4, 106.7, 99, 56.3, 55.9; IR (CHCl₃): ν_{max} 3420.2, 3051.9, 1646.6, 1275.1, 1050.2, 1024.4, 1004.5 cm⁻¹; ESI-MS: 255.15 [M+H]⁺.

2-(4-*tert*-Butylphenyl)-1*H*-benzo[*d*]imidazole (3f)⁵




Off white solid; 180 mg, 72%; ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.87 (s, 1H), 8.13 (d, *J* = 8Hz, 2H), 7.67 (d, *J* = 8Hz, 1H), 7.58 (d, *J* = 8Hz, 2H), 7.54 (d, *J* = 8Hz, 1H), 7.23 (t, *J* = 8Hz, 2H), 1.33 (s, 9H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 153, 1517, 144.1, 135.3, 127.9, 126.7, 126.2, 122.8, 122.1, 119.2, 111.7, 35, 31.5; IR (CHCl₃): ν_{max} 3399, 1675.4, 1275.6, 1023.1, 996.4 cm⁻¹; ESI-MS (*m/z*): 251.67 [M+H]⁺

6-Bromo-4-chloro-2-phenyl-1*H*-benzo[*d*]imidazole (3l)



Off white solid; 214 mg, 70%; ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.40 (s, 1H), 8.29-8.19 (m, 2H), 7.68 (s, 1H), 7.57 (t, *J* = 8Hz, 3H), 7.46 (s, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 153.4, 140.6, 137.4, 131, 129.6, 129.5, 127.3, 124.4, 124.2, 114.6, 113.7; ESI-MS (*m/z*): 306.95 [M+H]⁺.

2-Phenylquinoxaline (5a)⁷



Off white solid; 154.6 mg, 75%, m.p 72-72 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.35 (s, 1H), 8.23-8.13 (m, 4H), 7.82-7.74 (m, 2H), 7.60-7.52 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 151.8, 143.4, 142.3, 141.6, 136.8, 130.3, 130.2, 129.6, 129.5, 129.1, 127.6 cm⁻¹; ESI-MS (*m/z*): 207 [M+H]⁺HRMS (ESI-TOF) m/z: [M+ H]⁺calcd for C₁₄H₁₁N₂ 207.0917; Found 207.0923.

2-(4-Bromophenyl)quinoxaline (5b)⁷




Light brown solid; 215.8 mg, 76%; m.p 138-140°C (138 °C)¹⁰; ¹H NMR (400 MHz, MeOD): δ 9.42 (s, 1H), 8.24 (d, *J* = 8 Hz, 2H), 8.17 (d, *J* = 8 Hz, 2H), 8.13 (d, *J* = 8 Hz, 2H), 7.90-7.83 (m, 2H), 7.78 (d, *J* = 12 Hz, 2H); ¹³CNMR (100 MHz, MeOD): δ 150.8, 142.8, 142, 141.2, 135.5, 132, 130.5, 129.9, 129.1, 128.9, 128.3, 124.6 cm⁻¹; ESI-MS (*m/z*): 285 [M+2H]⁺; HRMS (ESI-TOF) m/z: [M+ H]⁺calcd for C₁₄H₁₀BrN₂ 285.0022; Found 285.0026.

2-(4-Methoxyphenyl)quinoxaline (5c)⁷




Off white solid; 153.5 mg, 65%; m.p 96-98 °C (97-98 °C)¹⁰; ¹H NMR (400 MHz, MeOD): δ 9.33 (s, 1H), 8.22 (d, *J* = 8Hz, 2H), 8.10-8.04 (m, 2H), 7.82-7.76 (m, 2H), 7.12 (d, *J* = 2H), 3.90 (s, 3H); ¹³C NMR (100 MHz, MeOD): δ 161.9, 151.7, 142.8, 142.1, 140.5, 130.3, 129.1, 128.8, 128.7, 128.1, 114.2, 54.5; ESI-MS (*m/z*): 237 [M+H]⁺.

2-(4-Fluorophenyl)quinoxaline (5d)⁸




Off white solid; 172.5 mg, 77%, m.p 128-131; ¹H NMR (400 MHz, CDCl₃): δ 9.28 (s, 1H), 8.21-8.18 (m, 2H), 8.14-8.11 (m, 2H), 7.79-7.74 (m, 2H), 7.27-7.23 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 165.5 (*J*_{CF} = 249 Hz), 150.7, 142.9, 142.2, 141.5, 132.9 (⁴*J*_{CF} = 3Hz), 130.4, 129.6, 129.5, 129.4, 129.1, 116.3 (²*J*_{CF} = 21 Hz); ESI-MS (*m/z*): 225 [M+H]⁺.

6-Nitro-2-phenylquinoxaline (5e)⁹



Off white solid; 163.2 mg, 65%, m.p 199-202; ^1H NMR (400 MHz, CDCl_3): δ 9.53 (s, 1H), 9.06 (s, 1H), 8.60 (d, $J = 1\text{ Hz}$, 1H), 8.33-8.28 (m, 3H), 7.65-7.63 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 145.5, 140.1, 131.1, 129.4, 127.9, 125.6, 123.8; ESI-MS (m/z): 252 [M+H]⁺.

6,7-Dichloro-2-phenylquinoxaline (5f)⁸




White solid; 186 mg, 68%, m.p 158-161; ^1H NMR (400 MHz, CDCl_3): δ 9.34 (s, 1H), 8.30 (s, 1H), 8.26 (s, 1H), 8.22 (d, $J = 8\text{ Hz}$, 2H), 7.61-7.59 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 152.6, 144.3, 141.1, 140.3, 136, 134.9, 134, 130.8, 130.2, 129.8, 129.3, 127.6; ESI-MS (m/z): 275 [M+H]⁺; HRMS (ESI-TOF) m/z: [M+H]⁺calcd for $\text{C}_{14}\text{H}_9\text{Cl}_2\text{N}_2$ 275.0137; Found 275.0144.

6,7-Dichloro-2-(4-methoxyphenyl)quinoxaline (5g)




Off white solid; 185 mg, 61%, m.p 203-205; ^1H NMR (400 MHz, CDCl_3): δ 9.29 (s, 1H), 8.24-8.17 (m, 4H), 7.11-7.09 (m, 2H), 3.93 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 161.9, 152.2, 143.9, 141.1, 139.6, 134.7, 133.3, 129.9, 129.7, 129.1, 128.4, 114.7, 55.5; ESI-MS (m/z): 305 [M+H]⁺.

6,7-Dichloro-2-(4-fluorophenyl)quinoxaline (5h)



Off white solid; 207 mg, 71%; ^1H NMR (400 MHz, CDCl_3): δ 9.31 (s, 1H), 8.28 (d, $J = 12$ Hz, 1H), 8.24-8.19 (m, 2H), 7.31-7.25 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.8 ($J_{\text{CF}1} = 249$ Hz), 151.5, 143.8, 140.9, 140.2, 135.1, 134.1, 132.1, 130.1, 129.8, 129.7, 116.5 ($J_{\text{CF}2} = 22$ Hz); ESI-MS (m/z): 292 [M+H] $^+$; HRMS (ESI-TOF) m/z: [M+H] $^+$ calcd for $\text{C}_{14}\text{H}_8\text{Cl}_2\text{FN}_2$ 293.0043; Found 293.0035.

6,7-Dimethyl-2-phenylquinoxaline (5i)⁸



Off white solid; 170.9 mg, 73%; ^1H NMR (400 MHz, CDCl_3): δ 9.47 (s, 1H), 8.32-8.30 (m, 2H), 7.92 (s, 1H), 7.89 (s, 1H), 7.62-7.56 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3): 150.5, 143.1, 141.4, 140.8, 140.7, 136.8, 130.6, 129.6, 128.6, 128.2, 127.7, 20.3; ESI-MS (m/z): 235 [M+H] $^+$.

2-(4-Fluorophenyl)-6,7-dimethylquinoxaline (5j)¹⁰



Off white solid; 191.6 mg, 76%; ^1H NMR (400 MHz, CDCl_3): δ 9.17 (s, 1H), 8.18-8.14 (m, 2H), 7.86 (d, $J = 8$ Hz, 2H), 7.25 (t, $J = 8$ Hz, 2H), 2.50 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3): δ 165.25 ($J_{\text{CF}1} = 248$ Hz), 149.8, 141.9, 141.1, 140.9, 140.2, 129.3, 129.2, 128.5, 128.1, 116.2 ($J_{\text{CF}2} = 21$ Hz), 20.4, 20.3; ESI-MS (m/z): 253 [M+H] $^+$. HRMS (ESI-TOF) m/z: [M+H] $^+$ calcd for $\text{C}_{16}\text{H}_{14}\text{FN}_2$ 253.1136; Found 253.1146.

2-(4-Chlorophenyl)-6,7-dimethylquinoxaline (5k)¹⁰




Off white solid; 195.6 mg, 73%; ^1H NMR (400 MHz, CDCl_3): δ 9.19 (s, 1H), 8.14 (d, J = 8 Hz, 2H), 7.89 (d, J = 12 Hz, 2H), 7.54 (d, J = 2H), 2.53 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3): δ 149.7, 141.9, 141.1, 140.6, 140.5, 135.5, 129.3, 128.6, 128.1, 20.4, 20.3; ESI-MS (m/z): 269 [$\text{M}+\text{H}]^+$; HRMS (ESI-TOF) m/z: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{14}\text{ClN}_2$ 269.0840; Found 269.0838.

2-(4-Methoxyphenyl)-6,7-dimethylquinoxaline (5l)⁸




Off white solid; 163.7 mg, 62%; ^1H NMR (400 MHz, CDCl_3): δ 9.19 (s, 1H), 8.16 (d, J = 8 Hz, 2H), 7.88 (s, 1H), 7.84 (s, 1H), 7.12 (d, J = 8 Hz, 2H), 3.91 (s, 3H), 2.51 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3): δ 161.2, 150.7, 142.1, 140.7, 140.1, 139.6, 129.6, 128.8, 128.5, 128.1, 114.5, 55.4, 20.4, 20.3; ESI-MS (m/z): 265 [$\text{M}+\text{H}]^+$.

6-Fluoro-2-phenylquinoxaline (5m)⁸



Off white solid; 67 mg, 30%; ^1H NMR (400 MHz, CDCl_3): δ 9.35 (s, 1H), 8.22-8.17 (m, 2H), 7.79 (d, J = 8Hz, 1H), 7.63-7.56 (m, 4H); ^{13}C NMR (100 MHz, CDCl_3): δ 163.76 ($J_{\text{CF}1}$ = 250 Hz), 151.4, 144.1, 142.1, 139.5, 131.7, 130.3, 129.2, 122.4, 120.8, 120.6, 112.8 ($J_{\text{CF}2}$ = 22 Hz); ESI-MS (m/z): 225 [$\text{M}+\text{H}]^+$ HRMS (ESI-TOF) m/z: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{10}\text{FN}_2$ 225.0823; Found 225.0829.

7-Fluoro-2-phenylquinoxaline (5m)⁸




Off white solid; 89 mg, 40%; ¹H NMR (400 MHz, CDCl₃): δ 9.27 (s, 1H), 8.18 (d, *J* = 8 Hz, 2H), 8.11 (dd, *J* = 4, 8 Hz, 1H), 7.76-7.74 (m, 1H); 7.57-7.48 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 164.1 (*J*_{CF1} = 201 Hz), 152.6, 144.1, 143.3, 142.7 (*J*_{CF4}=3 Hz), 138.9, 136.5, 131.3 (*J*_{CF3} = 8 Hz), 130.6, 129.3, 127.7, 120.1, 113.2 ESI-MS (*m/z*): 225 [M+H]⁺.

6-Chloro-2-phenylquinoxaline (5n)⁷



Off white solid; 60 mg, 25%, ¹H NMR (400 MHz, CDCl₃): δ 9.36 (s, 1H), 8.23-8.21 (m, 2H), 8.15 (m, 2H), 7.77 (dd, *J* = 4, 8 Hz, 1H), 7.63-7.56 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 151.9, 144.2, 141.8, 140.8, 136.3, 135.2, 131.3, 130.8, 130.4, 129.4, 128.0, 127.5, ESI-MS (*m/z*): 241 [M+H]⁺; HRMS (ESI-TOF) m/z: [M+ H]⁺ calcd for C₁₄H₁₀ClN₂ 241.0527; Found 241.0538.

7-Chloro-2-phenylquinoxaline (5n¹)⁷




Off white solid; 103 mg, 43%; m.p 104-106 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.33 (s, 1H), 8.22-8.20 (m, 2H), 8.18 (d, *J* = 4 Hz, 1H), 8.08 (d, *J* = 8 Hz, 1H), 7.72 (dd, *J* = 4, 8 Hz, 1H), 7.62-7.55 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 152.6, 143.4, 142.7, 140.0, 136.3, 136.1, 130.6, 130.5, 130.3, 129.2, 128.5, 127.6; ESI-MS (*m/z*): 241 [M+H]⁺.

2-(4-Chlorophenyl)quinoxaline (5o)⁷



Off white solid; 180 mg, 75%; ¹H NMR (400 MHz, CDCl₃): δ 9.30 (s, 1H), 8.17-8.12 (m, 4H), 7.83-7.75 (m, 2H), 7.56 (d, *J* = 12 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 149.5, 141.8, 141.1, 140.6, 135.5, 134.1, 129.4, 128.7, 128.5, 128.3, 128.1, 127.7; ESI-MS (*m/z*): 241 [M+H]⁺; HRMS (ESI-TOF) *m/z*: [M+ H]⁺ calcd for C₁₄H₁₀ClN₂ 241.0527; Found 241.0536.

5,7-Dimethyl-2-phenylquinoxaline (5p)



Off white solid; 75 mg, 32%; ¹H NMR (400 MHz, CDCl₃): δ 9.28 (s, 1H), 8.21 (d, *J* = 8 Hz, 2H), 7.79 (s, 1H), 7.60-7.51 (m, 3H), 7.44 (s, 1H), 2.81 (s, 3H), 2.58 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): 151.3, 142.6, 141.1, 140.4, 139.3, 137.1, 136.7, 132, 129.9, 129.1, 127.5, 126.4, 21.9, 17.2; ESI-MS (*m/z*): 235 [M+H]⁺; HRMS (ESI-TOF) *m/z*: [M+ H]⁺ calcd for C₁₆H₁₅N₂ 235.1230; Found 235.1236.


6,8-Dimethyl-2-phenylquinoxaline (5p¹)




Off white solid; 82 mg, 35%; ¹H NMR (400 MHz, CDCl₃): δ 9.29 (s, 1H), 8.27 (d, *J* = 8 Hz, 2H), 7.73 (s, 1H), 7.59-7.49 (m, 3H), 7.46 (s, 1H), 2.85 (s, 3H), 2.57 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): 149.4, 142.5, 141.8, 139.8, 139.7, 137.3, 137.2, 132.5, 129.8, 129.0, 127.3, 125.7, 21.9, 16.9; ESI-MS (*m/z*): 235 [M+H]⁺.

Section 2. Scanned ^1H NMR, ^{13}C NMR, and HRMS Spectra

^1H NMR of 2-phenyl-1H-benzo[d]imidazole (3a)




Expansion of aromatic region of ^1H NMR of 2-phenyl-1H-benzo[d]imidazole (3a)




Parameter	Value
1 Data File Name	C:/ Users/Firdous/AppData/Local/Temp/Rar\$DR15.656/Project_01/Visible Light/Mediated Benzimidazole Synthesis/Spec_Data/RV_RS_001/NMR/10/fd
2 Title	NMR
3 Comment	rv-rs-001 PROTON DMSO (D:\CIL\P.V.Bharatam_108\NMR\2017\Aug) Administrator 12
4 Origin	Bruker BioSpin GmbH
5 Owner	Administrator
6 Site	
7 Spectrometer	spect
8 Author	
9 Solvent	DMSO
10 Temperature	673.2
11 Pulse	2g30
12 Sequence	
13 Number of Scans	16
14 Receiver Gain	203
15 Relaxation Delay	1.0000
16 Pulse Width	12.2000
17 Acquisition Time	3.9846
18 Acquisition Date	2017-08-22T17:04:19
19 Modification Date	2017-08-22T11:34:20
20 Spectrometer Frequency	400.13
21 Spectral Width	8223.7
22 Lowest Frequency	-1640.9
23 Nucleus	1H
24 Acquired Size	32768
24 Spectral Size	65536


¹³C NMR of 2-phenyl-1H-benzo[d]imidazole (3a)




¹H NMR of 2-(4-methylphenyl)-1H-benzo[d]imidazole (3b)




Expansion of aromatic region of ^1H NMR of 2-(4-methylphenyl)-1*H*-benzo[d]imidazole (3b)




¹³C NMR of 2-(4-methylphenyl)-1H-benzo[d]imidazole (3b)




¹H NMR of 5, 6-dichloro-2-phenyl-1H-benzo[d]imidazole (3i)




Expansion of the aromatic region of the ¹H NMR of 5,6-dichloro-2-phenyl-1H-benzo[d]imidazole (3i)




¹³C NMR of 5,6-dichloro-2-phenyl-1H-benzo[d]imidazole (3i)




¹H NMR of 5,6-dimethyl-2-phenyl-1H-benzo[d]imidazole (3j)




Expansion of the aromatic region of the ^1H NMR of 5, 6-dimethyl-2-phenyl-1H-benzo[d]imidazole (3j)




^{13}C NMR of 5,6-dimethyl-2-phenyl-1H-benzo[d]imidazole (3j)




¹H NMR of 5-nitro-2-phenyl-1H-benzo[d]imidazole (3g)




Expansion of the aromatic region of the ¹H NMR of 5-nitro-2-phenyl-1H-benzo[d]imidazole (3g)




¹³C NMR of 5-nitro-2-phenyl-1H-benzo[d]imidazole (3g)




¹H NMR spectra of 5-chloro-6-nitro-2-phenyl-1H-benzo[d]imidazole (3k)




¹³C NMR of 5-chloro-6-nitro-2-phenyl-1H-benzo[d]imidazole (3k)




HRMS of 5-chloro-6-nitro-2-phenyl-1H-benzo[d]imidazole (3k)




¹H NMR of 2-(3-chlorophenyl)-1H-benzo[d]imidazole (3c)




Expansion of the aromatic region of the ^1H NMR of 2-(3-chlorophenyl)-1H-benzo[d]imidazole (3c)




¹³C NMR of 2-(3-chlorophenyl)-1H-benzo[d]imidazole (3c)




¹H NMR of 2-(3-chlorophenyl)-5-nitro-1H-benzo[d]imidazole (3h)




Expansion of the aromatic region of the ¹H NMR of 2-(3-chlorophenyl)-5-nitro-1H-benzo[d]imidazole (3h)




¹³C NMR of 2-(3-chlorophenyl)-5-nitro-1H-benzo[d]imidazole (3h)




¹H NMR of 2-(2-methylphenyl)-1H-benzo[d]imidazole (3d)




Expansion of the aromatic region of the ^1H NMR of 2-(2-methylphenyl)-1H-benzo[d]imidazole (3d)




¹³C NMR of 2-(2-methylphenyl)-1H-benzo[d]imidazole (3d)




¹H NMR of 2-(2,4-dimethoxyphenyl)-1H-benzo[d]imidazole (3e)




Expansion of the aromatic region of the ^1H NMR of 2-(2,4-dimethoxyphenyl)-1*H*-benzo[*d*]imidazole (3e)




^{13}C NMR of 2-(2,4-dimethoxyphenyl)-1*H*-benzo[*d*]imidazole (3e)




¹H NMR of 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole (3f)




Expansion of the aromatic region of the ¹H NMR of 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole (3f)



¹³C NMR of 2-(4-(*tert*-butyl)phenyl)-1*H*-benzo[*d*]imidazole (3f)




¹H NMR of 6-bromo-4-chloro-2-phenyl-1H-benzo[d]imidazole (3l)



Expansion of the aromatic region of the ¹H NMR of 6-bromo-4-chloro-2-phenyl-1H-benzo[d]imidazole (3l)


NMR
fas-48
PROTON DMSO {D:\CIL\P.V.Bharatam_108\NMR\2018\Apr} Administrator 38



Parameter	Value
1 Data File Name	C:/Users/Firdous/AppData/Local/Temp/Rar\$DR90.828/Project_01Visible Light Mediated Benzimidazole Synthesis/Spec_Data/RV-RS-148/NMR/10/fid
2 Title	NMR
3 Comment	fas-48 PROTON DMSO {D:\CIL\P.V.Bharatam_108\NMR\2018\Apr} Administrator 38
4 Origin	Bruker BioSpin GmbH
5 Owner	Administrator
6 Site	
7 Spectrometer	spect
8 Author	
9 Solvent	DMSO
10 Temperature	293.2
11 Pulse Sequence	zg30
12 Number of Scans	16
13 Receiver Gain	181
14 Relaxation Delay	1.0000
15 Pulse Width	12.2000
16 Acquisition Time	3.9846
17 Acquisition Date	2018-04-13T18:15:44
18 Modification Date	2018-04-13T12:45:46
19 Spectrometer Frequency	400.13
20 Spectral Width	8223.7
21 Lowest Frequency	-1640.9
22 Nucleus	1H
23 Acquired Size	32768
24 Spectral Size	65536


¹³C NMR of 6-bromo-4-chloro-2-phenyl-1H-benzo[d]imidazole (3l)

NMR
fas-48
C13CPD DMSO {D:\CIL\P.V.Bharatam_108\NMR\2018\Apr} Administrator 38




Parameter	Value
1 Data File Name	C:/Users/Firdous/AppData/Local/Temp/Rar\$DR17.4484/Project_01Visible Light Mediated Benzimidazole Synthesis/Spec_Data/RV-RS-148/NMR/12/fid
2 Title	NMR
3 Comment	fas-48 C13CPD DMSO {D:\CIL\P.V.Bharatam_108\NMR\2018\Apr} Administrator 38
4 Origin	Bruker BioSpin GmbH
5 Owner	Administrator
6 Site	
7 Spectrometer	spect
8 Author	
9 Solvent	DMSO
10 Temperature	293.8
11 Pulse Sequence	zgpg30
12 Number of Scans	1024
13 Receiver Gain	203
14 Relaxation Delay	2.0000
15 Pulse Width	9.5000
16 Acquisition Time	1.3631
17 Acquisition Date	2018-04-14T12:04:47
18 Modification Date	2018-04-14T06:34:48
19 Spectrometer Frequency	100.62
20 Spectral Width	24038.5
21 Lowest Frequency	-1958.4
22 Nucleus	13C
23 Acquired Size	32768
24 Spectral Size	65536

¹H NMR of 2-Phenylquinoxaline (5a)




Parameter	Value
1 Data File Name	C:/Users/Firdaus/Desktop/Quinoxalines/f1-10/fd
2 Title	fr-1
3 Comment	PROTON CDCB (D1,C1), P,Vibharatam_10 8,(NMR),2018, May
4 Origin	Bruker BioSpin GmbH
5 Owner	Administrator
6 Site	
7 Spectrometer	spect
8 Author	
9 Solvent	CDCB
10 Temperature	299.0
11 Pulse Sequence	zg30
12 Number of Scans	16
13 Receiver Gain	161
14 Relaxation Delay	1.0000
15 Pulse Width	12.0000
16 Acquisition Time	3.9846
17 Acquisition Date	2018-05-25T18: 42:14
18 Modification Date	2018-05-25T18: 42:14
19 Spectrometer Frequency	400.13
20 Spectral Width	8223.7
21 Lowest Frequency	-1640.9
22 Nucleus	1H
23 Acquired Size	32768
24 Spectral Size	65536

Expansion of the aromatic region of the ^1H NMR of 2-Phenylquinoxaline (5a)



¹³C NMR of 2-Phenylquinoxaline (5a)



HRMS of 2-Phenylquinoxaline (5a)

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

33 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass)

Elements Used:

Elements used:
C: 11-30 H: 7-35 N: 0-5 F: 0-3


Sample Name : FS-1

Test Name : HRMS-1

071119-FS-1 20 (0.211) AM2 (Ar,22000.0,0.00,0.00); Cm (20:26)

1: TOF MS ES+

1.04e+008




Minimum: -1.5

Maximum: 5.0 5.0 50.0


Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
------	------------	-----	-----	-----	-------	------	----------	---------

207.0923 207.0922 0.1 0.5 10.5 1352.3 n/a n/a C14 H11 N2


¹H NMR of 2-(4-Bromophenyl)quinoxaline (5b)




Expansion of the aromatic region of the ¹H NMR of 2-(4-Bromophenyl)quinoxaline (5b)




¹³C NMR of 2-(4-Bromophenyl)quinoxaline (5b)




HRMS of 2-(4-Bromophenyl)quinoxaline (5b)




¹H NMR of 2-(4-methoxyphenyl)quinoxaline (5c)




Expansion of the aromatic region of the ¹H NMR of 2-(4-methoxyphenyl)quinoxaline (5c)




¹³C NMR of 2-(4-methoxyphenyl)quinoxaline (5c)




¹H NMR of 2-(4-fluorophenyl)quinoxaline (5d)




Expansion of the aromatic region of ^1H NMR of 2-(4-fluorophenyl)quinoxaline (5d)




¹³C NMR of 2-(4-fluorophenyl)quinoxaline (5d)




¹H NMR of 6-nitro-2-phenylquinoxaline (5e)




Expansion of the aromatic region of the ¹H NMR of 6-nitro-2-phenylquinoxaline (5e)




¹³C NMR of 6-nitro-2-phenylquinoxaline (5e)




¹H NMR of 6,7-dichloro-2-phenylquinoxaline (5f)



Expansion of the aromatic region of the ^1H NMR spectra of 6,7-dichloro-2-phenylquinoxaline (5f)



^{13}C NMR of 6,7-dichloro-2-phenylquinoxaline (5f)



HRMS of 6,7-dichloro-2-phenylquinoxaline (5f)

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 50.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

41 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass)

Elements Used:

C: 11-30 H: 7-35 N: 0-5 Cl: 0-2

Sample Name : FS-2


IITRPR

XEVO G2-XS QTOF


Test Name : HRMS-1

071119-FS-2 76 (0.726) AM (Top,4, Ar,10000.0,0.00,0.00); Cm (76:88)


1: TOF MS ES+
1.12e+008




¹H NMR of 6,7-dichloro-2-(4-methoxyphenyl)quinoxaline (5g)




Expansion of the aromatic region of the ^1H NMR of 6,7-dichloro-2-(4-methoxyphenyl)quinoxaline (5g)




¹³C NMR of 6,7-dichloro-2-(4-methoxyphenyl)quinoxaline (5g)




¹H NMR of 6,7-dichloro-2-(4-fluorophenyl)quinoxaline (5h)



Expansion of the aromatic region of the ¹H NMR of 6,7-dichloro-2-(4-fluorophenyl)quinoxaline (5h)



¹³C NMR of 6,7-dichloro-2-(4-fluorophenyl)quinoxaline (5h)



HRMS of 6,7-dichloro-2-(4-fluorophenyl)quinoxaline (5h)

Elemental Composition Report


Page 1

Single Mass Analysis


Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0
Element prediction: Off
Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions
152 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass)


152 formula(e) evaluated with 1 results within limits
Elements Used:
C: 11-30 H: 7-35 N: 0-5 F: 0-3 Cl: 0-2
Sample Name : ES-11




¹H NMR of 6,7-dimethyl-2-phenylquinoxaline (5i)




Expansion of the aromatic region of the ¹H NMR of 6,7-dimethyl-2-phenylquinoxaline (5i)




¹³C NMR of 6,7-dimethyl-2-phenylquinoxaline (5i)




¹H NMR of 2-(4-fluorophenyl)-6,7-dimethylquinoxaline (5j)



Expansion of the aromatic region of the ^1H NMR of 2-(4-fluorophenyl)-6,7-dimethylquinoxaline (5j)



^{13}C NMR of 2-(4-fluorophenyl)-6,7-dimethylquinoxaline (5j)



HRMS of 2-(4-fluorophenyl)-6,7-dimethylquinoxaline (5j)

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

52 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass)


Elements Used:

C: 11-30 H: 7-35 N: 0-5 F: 0-3

Sample Name : FS-10

XEVO G2-XS QTOF


1: TOF MS ES+
6.21e+007




Minimum: -1.5
Maximum: 5.0 5.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
253.1146	253.1141	0.5	2.0	10.5	1142.1	n/a	n/a	C16 H14 N


¹H NMR of 2-(4-chlorophenyl)-6,7-dimethylquinoxaline (5k)



Expansion of the aromatic region of the ^1H NMR spectra of 2-(4-chlorophenyl)-6,7-dimethylquinoxaline (5k)



^{13}C NMR of 2-(4-chlorophenyl)-6,7-dimethylquinoxaline (5k)



HRMS of 2-(4-chlorophenyl)-6,7-dimethylquinoxaline (5k)

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0

Element prediction: Off

Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

26 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass)

Elements Used:

C: 11-30 H: 7-35 N: 0-3 Cl: 0-2

Sample Name : FS-13


Test Name : HRMS-1

071119-FS-13 18 (0.183) AM2 (Ar,22000.0,0.00,0.00); Cm (18:21)


IITRPR

XEVO G2-XS QTOF


1: TOF MS ES+
4.41e+007




¹H NMR of 2-(4-Methoxyphenyl)-6,7-dimethylquinoxaline (5l)




Expansion of the aromatic region of the ^1H NMR spectra of 2-(4-Methoxyphenyl)-6,7-dimethylquinoxaline (5l)




^{13}C NMR of 2-(4-Methoxyphenyl)-6,7-dimethylquinoxaline (5l)




¹H NMR of 6-fluoro-2-phenylquinoxaline (5m)




Expansion of the aromatic region of the ¹H NMR of 6-fluoro-2-phenylquinoxaline (5m)




¹³C NMR of 6-fluoro-2-phenylquinoxaline (5m)




HRMS of 6-fluoro-2-phenylquinoxaline (5m)




¹H NMR of 7-fluoro-2-phenylquinoxaline ($5m^1$)




Expansion of the aromatic region of the ¹H NMR of 7-fluoro-2-phenylquinoxaline ($5m^1$)




¹³C NMR of 7-fluoro-2-phenylquinoxaline (5m¹)




¹H NMR of 6-Chloro-2-phenylquinoxaline (5n)



Expansion of the aromatic region of the ¹H NMR of 6-Chloro-2-phenylquinoxaline (5n)



¹³C NMR of 6-Chloro-2-phenylquinoxaline (5n)



Parameter	Value
1 Data File Name	E:/ Transferred New Folder/ Objective 2/ fas-4d-op1/ 12/ fid
2 Title	fas-4d-op1
3 Comment	fas-4d-op1 C13CPD CDCl3 (D:\CIL\P.V.Bharatam_10B\NMR\2018\Dec) Administrator 8
4 Origin	Bruker BioSpin GmbH
5 Owner	Administrator
6 Site	
7 Spectrometer	spect
8 Author	
9 Solvent	CDCl3
10 Temperature	673.2
11 Pulse Sequence	zpg30
12 Number of Scans	256
13 Receiver Gain	203
14 Relaxation Delay	2.0000
15 Pulse Width	9.5000
16 Acquisition Time	1.3631
17 Acquisition Date	2018-12-07T15:21:32
18 Modification Date	2018-12-07T15:21:32
19 Spectrometer	100.62
Frequency	
20 Spectral Width	24038.5
21 Lowest Frequency	-1958.4
22 Nucleus	¹³ C
23 Acquired Size	32768
24 Spectral Size	65536

HRMS of 6-Chloro-2-phenylquinoxaline (5n)

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0
Element prediction: Off
Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

33 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass)

Elements Used:

C: 11-30 H: 7-35 N: 0-5 Cl: 0-2

Sample Name : FAS-OP1


Test Name : HRMS-1

071119-FAS-OP1 16 (0.165) AM (Top.4, Ar,10000.0,0.00,0.00), Cm (16:19)

IITRPR

XEVO G2-XS QTOF


1: TOF MS ES+
3.19e+007




Minimum: -1.5
Maximum: 5.0 5.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
241.0538	241.0533	0.5	2.1	10.5	1195.8	n/a	n/a	C14 H10 N2 Cl


¹H NMR of 7-Chloro-2-phenylquinoxaline (**5n¹**)




Expansion of the aromatic region of the ¹H NMR of 7-Chloro-2-phenylquinoxaline (**5n¹**)




¹³C NMR of 7-Chloro-2-phenylquinoxaline (5n¹)




¹H NMR of 2-(4-Chlorophenyl)quinoxaline (5o)



Expansion of the aromatic region of the ^1H NMR of 2-(4-Chlorophenyl)quinoxaline (5o)



¹³C NMR of 2-(4-Chlorophenyl)quinoxaline (5o)



HRMS of 2-(4-Chlorophenyl)quinoxaline (5o)

Elemental Composition Report

Page 1

Single Mass Analysis


Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0
Element prediction: Off
Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions
33 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass)


Elements Used:

C: 11-30 H: 7-35 N: 0-5 Cl: 0-2


Sample Name : FS-12 ITRPR XEVO G2-XS QTOF
Test Name : HRMS-1
071119-FS-12 24 (0.245) AM2 (Ar,22000.0,0.00,0.00); Crn (24:29)
1: TOF MS ES+
8.60e+007




¹H NMR of 5,7-Dimethyl-2-phenylquinoxaline (5p)



Expansion of the aromatic region of the ¹H NMR of 5,7-Dimethyl-2-phenylquinoxaline (5p)



¹³C NMR of 5,7-Dimethyl-2-phenylquinoxaline (5p)



HRMS of 5,7-Dimethyl-2-phenylquinoxaline (5p)

Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 5.0 PPM / DBE: min = -1.5, max = 50.0
Element prediction: Off
Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions

33 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass)

Elements Used:

C: 11-30 H: 7-35 N: 0-5 Cl: 0-2

Sample Name : FS-4A


IITPRR

XEOV G2-XS QTOF

Test Name : HRMS-1

1: TOF MS ES+
4.41e+007


071119-FS-4A 24 (0.245) AM2 (Ar.22000.0.0.0.0.0); Cm (24.26)




Minimum: -1.5
Maximum: 5.0 5.0 50.0

Mass	Calc. Mass	mDa	PPM	DBE	i-FIT	Norm	Conf (%)	Formula
235.1236	235.1235	0.1	0.4	10.5	1153.9	n/a	n/a	C16 H15 N2


¹H NMR of 6,8-Dimethyl-2-phenylquinoxaline (5p¹)



Expansion of the aromatic region of the ¹H NMR of 6,8-Dimethyl-2-phenylquinoxaline (5p1)



¹³C NMR of 6,8-Dimethyl-2-phenylquinoxaline (5p¹)



3. References associated with ESI

1. S. Park, J. Jung, E. J. Cho; *Eur. J. Org. Chem.*, 2014, **2014**, 4148-4154.
2. R. Sharma, M. Abdullah, S. B. Bharate, *Asian J. Org. Chem.*, 2017, **6**, 1370–1374.
3. K. M. H. Nguyen, M. Largeron, *Eur. J. Org. Chem.*; 2016, 1025–1032.
4. K. Osowska, O. Š. Miljanić, *J. Am. Chem. Soc.*, 2011, **133**, 4, 724-727.
5. R. Zhang, Y. Qin, L. Zhang, S. Luo, *Org. Lett.*, 2017, **19**, 5629–5632.
6. B. Tanwar, P. Purohit, B.N. Raju, D. Kumar, D. N. Kommi, A. K. Chakraborti, *RSC Adv.*, 2015, **5**, 11873-11883.
7. L. J. Martin, A. L. Marzinzik, S. V. Ley, I. R. Baxendale, *Org. Lett.* 2011, **13**, 320-323.
8. J. Song, X. Li, Y. Chen, M. Zhao, Y. Dou, B. Chen, *Synlett*, 2012, **23**, 2416-2420.
9. J. Pogula, S. Laha, P. R. Likhari, *Catal. Lett.* 2017, 147, 2724-2735.
10. C. Zhang, Z. Xu, L. Zhang, N. Jiao, *Tetrahedron*, 2012, **68**, 5258-5262.